We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





10-Minute Sepsis Risk Stratification Test Introduced at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: 10-minute IntelliSep Sepsis Test (Photo courtesy of Cytovale)
Image: 10-minute IntelliSep Sepsis Test (Photo courtesy of Cytovale)

Emergency department (ED) physicians tasked with diagnosing sepsis, a dysregulated immune (white blood cell) response to infection that can be life threatening, often face a scarcity of information that could lead to over- or under-treatment. Now, a new instrument and sepsis risk stratification test launched at the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo could help address this challenge.

At AACC 2022, Cytovale (San Francisco, CA, USA) revealed its 510(k) pending Cytovale system and 10-minute IntelliSep sepsis risk stratification test, and also shared new data featuring the test. The Cytovale system directly analyzes white blood cells using rapid techniques that look at cell structure, which may make it faster and less expensive than other approaches. The IntelliSep test aims to simply and clearly determine the risk of a patient having sepsis using a biomechanical evaluation of white blood cells from a standard blood draw at presentation, generating results in under 10 minutes.

Microfluidic cell-handling techniques combined with the technological advances of high-speed imaging and machine learning allow the Cytovale system to analyze the biophysical properties of tens of thousands of leukocytes, yielding a score called the IntelliSep Index (ISI). The ISI results are stratified into three interpretation bands corresponding to regions of low (Green Band), intermediate (Yellow Band), and high (Red Band) risk for sepsis. Cytovale recently fulfilled the target enrollment of the CV-SQuISH-ED study involving the IntelliSep test at four clinical study sites across the country and has included the data from that study in a 510(k) submission to FDA. Data presented at AACC 2022 compared the ISI to ED diagnosis and indicated that the ISI could provide valuable information to help EDs rapidly triage patients more effectively.

“We’re excited to share the IntelliSep test with the global laboratory science community at AACC 2022. While nearly a dozen instruments have already been operated in clinical labs at facilities across the U.S., the next logical step now that the clinical validation study has been completed and our 510(k) filing has been submitted, is to engage more broadly with those who may benefit from our potentially critical and time-saving tool that could change the way emergency departments recognize and treat sepsis,” said Cytovale co-founder and CEO Ajay Shah. “We encourage all in attendance at the meeting to come learn about the investigational IntelliSep test and how it may address the need to more quickly and accurately assess and triage potential sepsis patients.”

Related Links:
Cytovale 

New
Gold Supplier
Quantitative Immunoassay Analyzer
FIA8000
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test
New
Infliximab Rapid Test
Quantum Blue Infliximab
New
Legionella Pneumophila Assay
C4Legio LFA

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.